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Background: Patients diagnosed with locoregionally advanced head and neck squamous cell carcinoma 
(LAHNSCC) regularly undergo staging with 18F-FDG PET/CT in our center. In cases of delays in radiotherapy 
(RT) planning CT more than 4 weeks after initial PET/CT or clinically suspected progress, PET/CT is repeated for 
restaging and as an RT planning reference. Our aim was to determine the impact of second-look PET/CT on stage 
migration, treatment change and RT planning. 
Methods: Consequent treatment changes were categorized as minor and major. Minor changes were defined as 
PET/CT-based modifications of RT plans, e.g., the addition of anatomical compartments, changes in high- and 
low-risk dose levels or both. Major changes included changes from curative to palliative treatment intent and 
alterations of interdisciplinary treatment plans, such as the addition of induction chemotherapy, switch to pri-
mary surgery, no treatment and/or the necessity of additional diagnostic work-up resulting in the postponement 
or cancellation of treatment. 
Results: Thirty-two newly diagnosed LAHNSCC patients who were treated between 2014 and 2018 underwent 
second-look PET/CT (median interval 42.5 days). Second-look PET/CT led to locoregional and distant upstaging 
in 3/32 and 1/32 patients, respectively. In 1/32 patients (3%), second-look PET/CT led to a palliative approach 
with systemic treatment. New lymph node metastases were discovered in 16 patients, 6 of whom also showed 
significant progression of the primary tumor, resulting in minor changes in 16 of the remaining 31 patients (52%) 
who were treated curatively. 
Conclusion: If RT treatment planning of LAHNSCC was delayed by more than 4 weeks after initial PET/CT staging 
or when progression was clinically suspected, a second look at 18FDG-PET/CT was performed. This led to changes 
in treatment planning in more than half of the cases, which is expected to directly influence oncologic outcomes.   
Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the 6th most 
common malignancy worldwide, and most patients require radio-
therapy (RT) as part of a single- or multimodal treatment concept [1–3]. 
Patients with locoregionally advanced HNSCC (LAHNSCC) diagnosed in 
our center undergo initial tumor staging with integrated 18F-fluo-
rodeoxyglucose positron emission tomography and computed tomog-
raphy (PET/CT) as part of the diagnostic work-up [4] before 
multidisciplinary tumor board presentation. If the RT planning CT is 
performed 4 weeks or more after the initial PET/CT due to logistic, 
medical and/or patient-related factors or in case of clinical suspicion for 
tumor progression, the PET/CT exam is repeated in the RT position. The 
underlying reason for such repeated PET/CT imaging is the aggressive 
biology and high dynamics of HNSCC, with a risk of upstaging in the 
interval due to locoregional and/or systemic progression [5,6]. Finally, 
our hope is to improve the RT planning accuracy, having up-to-date 
image information of the current tumor extent available. At our 
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institution, additional, parallel repeated magnetic resonance imaging 
(MRI) is usually omitted due to financial and logistical reasons. This 
practice was established as a standard in our center in 2014. The aim of 
this retrospective study was to determine the impact of second-look 
PET/CT on RT planning and changes in treatment indications. 
Methods and materials 
A retrospective chart and plan review of eligible patients who were 
diagnosed with two pretreatment PET/CTs and treated between 2014 
and 2018 was performed. Eligibility criteria were ≥ 18 years of age; 
histopathologically proven LAHNSCC of the oral cavity, oropharynx, 
larynx or hypopharynx in stages III-IVB (Union for International Cancer 
Control 7th edition); treatment indication for definitive RT (normo-
fractionated with concomitant chemotherapy or hyperfractionated); no 
induction chemotherapy or primary surgery; and no previous radiation 
to the neck. 
All patients kept a carbohydrate-free diet for at least 6 h before the 
PET/CT examination, and the blood glucose level was below 10 mmol/L 
before intravenous injection of 4–5 MBq 18F-fluorodeoxyglucose (FDG)/ 
kg body weight. PET/CT was performed with a standardized acquisition 
protocol using an integrated PET/CT system (Biograph mCT 128 True V, 
Siemens Medical Solutions, Germany). Emission images of the trunk 
(neck to the pelvis) were obtained 90 min after injection (5–7 bed po-
sitions, 2 min per bed position) followed by dedicated high-resolution 
PET acquisition of the head and neck region (1 bed position, axial 
coverage 21.6 cm, 10 min per bed position). All PET images were 
reconstructed using an iterative time-of-flight algorithm including point 
spread function correction (TrueX). PET images of the trunk were 
reconstructed with a matrix size of 200x200, 5 mm Gauss filtering and a 
voxel size of 4 mm. High-resolution PET images of the head and neck 
region were reconstructed with a matrix size of 512x512, 2 mm Gauss 
filtering and a voxel size of 1.6 mm. PET images were coregistered with a 
low-dose CT (120 kV, 80 mAs, reconstructed slice thickness 2 mm), 
which was also used for attenuation correction. In addition, all quali-
fying patients underwent an additional contrast-enhanced CT of the 
head and neck region (120 kV, 160 mAs, reconstructed slice thickness 2 
mm). 
In routine clinical practice, all PET/CTs were reviewed and reported 
by two board-certified physicians with more than 10 years of practice in 
oncological PET and PET/CT. The classification of lesions with FDG 
uptake as benign vs. malignant lesions was based on the integrated 
interpretation of metabolic (e.g., focal uptake, relative uptake intensity 
of primary tumor and possible metastatic lesions with respect to size- 
dependent partial-volume effects, activity distribution) and morpho-
logic imaging criteria (e.g., size and shape of lesions, infiltration of 
surrounding tissues, necrosis, extracapsular extension). 
Changes in the primary tumor, lymphatic spread and presence of 
distant metastases between two PET/CTs were extracted from the 
written original clinical reports. PET/CT-based treatment changes were 
categorized as minor and major treatment changes. Minor changes were 
defined as modifications of RT plans, e.g., the addition of anatomical 
compartments, the regional adjustment of dose levels or both. Major 
changes from curative to palliative treatment intent and alterations of 
interdisciplinary treatment plans included the addition of induction 
chemotherapy, switch to primary surgery, no treatment and/or the ne-
cessity of additional diagnostic work-up resulting in the postponement 
or cancellation of treatment. 
Minor and major changes were evaluated on a case-by-case basis and 
reported categorically. The predictive value of the time interval between 
two PET/CTs for such changes in treatment was analyzed with logistic 
regression. Metabolic tumor volume (MTV) for the primary tumor and 
involved lymph nodes was calculated based on the externally validated 
method defined by Castelli et al. [7]. MTV was determined based on 
relative thresholds of 35% mean standard uptake value (SUVmean) for 
primary tumors and 44% for lymph nodes. These thresholds were 
reported with their high prognostic value regarding overall survival. 
JMP (version 14.0; SAS Institute, Germany) was used for statistical 
analyses. 
Results 
Thirty-two newly diagnosed LAHNSCC patients who were treated 
between 2014 and 2018 underwent a second look PET/CT for restaging 
and RT planning. Patient and tumor characteristics are provided in 
Table 1. The median interval between the staging and second look PET/ 
CT examinations was 42.5 days (interquartile range: 35.25–55; range: 
16–114). Two patients underwent a second-look PET/CT in <4 weeks 
due to clinical suspicion of tumor progression. The reason for the >4- 
week delay varied from logistic (i.e., regarding appointment sched-
uling), medical (need for further work-up) or patient-related factors. 
However, it was not completely possible to retrospectively reconstruct 
the exact reasons for delay. 
Major treatment change occurred in 1/32 cases. The patient was 
diagnosed with new distant metastases after an interval of 66 days be-
tween both examinations and had undergone upfront neck dissection for 
an N3 lymph node conglomerate in this time period. PET/CT findings 
finally led to a palliative approach with systemic treatment instead of 
initially planned radiochemotherapy. Of the remaining 31 patients, 3 
underwent upfront neck dissection between two PET/CTs, and the 
change in their nodal status was disregarded for the analyses of nodal 
stage migration or treatment changes. Second look PET/CT led to nodal 
upstaging in 3/29 (10%) cases. Nodal upstaging accounted for stage 
migration as cN1 → cN2b (75 days between both PET/CTs), cN2b → 
cN2c (40 days) and cN0 → cN2b (43 days). None of the two patients who 
underwent the second-look PET/CT earlier than 4 weeks (16 and 22 
days) due to clinical suspicion of progress were categorized as minor or 
major treatment changes. 
Among the 31 cases continuing with curative treatment, minor 
treatment changes occurred in 16/31 (52%) patients. New lymph node 
metastases were detected in all 16 cases, of which 6 also showed evident 
progression of the primary tumor size without changes in cT stage. The 
numbers of new lymph nodes (number of corresponding cases) were 1 
(n = 8), 2 (n = 4), 3 (n = 1), 5 (n = 2) and 6 (n = 1). The numbers of 
newly involved lymphatic levels [8] (number of corresponding cases) 
Table 1 
Initial patient and tumor characteristics.  
Parameter Distribution 
Median age (range) 64 (27–83) 
Female/male 11 (34%)/21 (66%) 
Tumor subsite  
Oral cavity 9 (28%) 
Oropharynx (HPV− ) 12 (38%) 
Oropharynx (HPV + ) 4 (13%) 
Larynx 3 (9%) 
Hypopharynx 4 (13%) 
Grade  
2 17 (53%) 
3 13 (41%) 
X 2 (6%) 
cT stage*  
2 7 (22%) 
3 10 (31%) 
4a 14 (44%) 
4b 1 (3%) 
cN stage*  
0 5 (16%) 
1 3 (9%) 
2b 9 (28%) 
2c 14 (44%) 
3 1 (3%) 
HPV: human papillomavirus association. 
* staging according to the Union for International Cancer Control, 
7th edition. 
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were 1 (n = 2), 2 (n = 4), 3 (n = 1), 4 (n = 1) and 5 (n = 1). The mean 
increase in the primary tumor MTV and the sum of involved lymph 
nodes were 6.7 cm3 (range: − 2.5 – 116.5 cm3) and 2.80 cm3 (range: 
− 4.3 – 50.7 cm3), respectively (Fig. 1). Modifications of the initially 
intended RT volumes and changes in involved lymphatic levels are 
summarized in Table 2. Images of an example case are demonstrated in 
Fig. 2. 
The time interval between two PET/CTs was not predictive of the 
occurrence of any treatment change (R2: 0.002; p = 0.768). 
Discussion 
To the best of our knowledge, this is the first study to investigate the 
value of a second-look PET/CT on stage migration and changes in 
treatment prior to definitive radiochemotherapy for LAHNSCC. Despite 
already benefitting from an initial PET/CT examination in terms of 
staging, minor treatment changes were necessary in more than half of 
the cases after the second look PET/CT. Regional and distant upstaging 
were seen in 10% and 3%, respectively. Half of the patients were diag-
nosed with newly involved lymph nodes, and one-third of the patients 
with additional lymphatic levels presented regional metastases. This led 
to substantial changes in the RT-plans. Interestingly, no predictive value 
of the time interval between two PET/CTs for treatment change was 
observed, which is likely due to the limited sample size. Therefore, it is 
not possible to define an optimal time threshold to recommend a second 
PET/CT after a given delay. It is also worth noting that no upstaging 
occurred in cT staging, although the volume increase of the primary 
tumors was greater than the volume increase of the sum of the involved 
lymph nodes with the missing values of the patients who underwent 
upfront neck dissection (6.7 cm3 vs. 2.80 cm3 on average, respectively). 
Another observation was that there seemed to be no clear correlation 
between the MTV changes and the emergence of newly involved lymph 
nodes. Moreover, some total MTV volumes even decreased despite the 
newly detected involved lymph nodes. This indicates that even the use of 
identical SUV thresholds on paired images with the same acquisition 
protocols may still yield such deviations. 
The use of 18FDG-PET/CT is considered a part of the initial 
investigations of LAHNSCC in the international guidelines for HNSCC 
[2,3] regarding the possibility of stage migration or in case of a carci-
noma of an unknown primary. In our center, it is an integral part of 
primary staging prior to surgery or RT along with physical examination, 
panendoscopy under general anesthesia and MRI for LAHNSCC. RT 
planning is based on the integrated findings of all these examinations. 
Both MRI and PET/CT are fused with the contrast-enhanced simulation 
CT. Despite the superior anatomical resolution and soft-tissue contrast of 
MRI, PET/CT is repeated in cases of delays between the initial imaging 
and the simulation CT. Unfortunately, it is not financially possible to 
repeat both imaging modalities. We prefer to scan the whole body for 
possible distant metastases through PET/CT followed by dedicated high- 
resolution PET acquisition of the head and neck region. Additionally, 
MRI is substantially hampered by dental artifacts, which is quite rele-
vant for the visualization of the oral cavity and some oropharyngeal 
tumors. Moreover, according to our experience, dedicated high- 
resolution PET/CT of the head and neck region appears at least non-
inferior or even superior to MRI and CT for the detection of pathologi-
cally involved lymph nodes and distant metastases and helps to detect 
second primary malignancies [9,10,19,11–18]. On the other hand, the 
anatomical resolution, tissue contrast and availability of different 
functional imaging sequences make MRI the superior modality for the 
identification and demarcation of primary tumors [20]. 
Until now, some studies have investigated the impact of PET or PET/ 
CT on clinical decision-making. Generally, approximately 30% of the 
original treatment decisions may be amended with the addition of PET 
[21–24]. In a recent study, PET/CT led to changes in nodal RT volumes 
in 10% of the study population (n = 60). Most detected occult nodal 
metastases on initially cN0 necks (26%) were of those with oral cavity 
tumors [25]. The cost-effectiveness of PET/CT for the initial staging of 
HNSCC was demonstrated, including but not limited to cN0 stage, which 
is reported to be approximately $2500 per quality-adjusted life-year 
[26–28]. The phase III PET-NECK trial also demonstrated the feasibility 
and cost-effectiveness of PET/CT in response evaluation after radio-
chemotherapy [29]. 
Our cohort only consisted of LAHNSCC cases without any stage I-II 
tumors. It might be expected that early-stage tumors would benefit less 
Fig. 1. Changes in primary tumor MTV, sum of involved nodes MTV and sum of all MTVs Description of Fig. 1: A: Primary tumor MTVs. B: Sum of the involved node 
MTVs. C: Sum of both MTVs. Each left Y-axis indicates the MTVs on the first PET/CTs, and the right side indicates the MTVs on the second PET/CTs in cc. Black lines 
correspond to the cases without any minor or major changes. The green lines and the red line represent the patients with minor and major changes, respectively. The 
four small red dashes on the left-hand Y-axes of Panels B and C indicate the patients who underwent upfront neck dissection after the first PET/CT. (For interpretation 
of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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from a second look PET/CT because of exponential tumor growth. In 
contrast, it is also possible that more upstaging would occur on the basis 
of a neck initially with no (cN0) or a lower (cN1–2a) burden of regional 
metastases. An upstaging in an already cN ≥ 2b case is less likely than a 
patient with cN0–2a because any newly emerging involved lymph nodes 
would upstage the disease in the latter case. Moreover, the clinical 
impact of upstaged early-stage HNSCC would be higher because a 
unimodal treatment concept would be switched to a multimodal 
Table 2 
Individual tumor characteristics at the time of first and second PET/CT.  














1 T3 cN3 Hypopharynx 
Grade 3 
R: II, II, IVA 
L: - 
UFND  1.7 UFND cM1 → major Not 
applicable 





L: -  
− 0.8 0 no no 
3 T3 N2c Larynx 
Grade 2 
R: II, Vc 
L: Ib, II, III, Vc 
R: II, Vc 
L: Ib, II, III, Vc  
− 1.6 − 1.5 no no 
4 T3 N2c Larynx 
Grade 2 
R: I, II, III, IVA 
L: II, III 
R: I, II, III, IVA 
L: II, III  
3.8 <0.1 no no 





L: -  
0.5 0 no no 





L: -  
− 0.4 0 no no 





L: -  
2.4 0 no no 
8 T4a N2c Oropharynx HPV- 
Grade 2 
R: II, III 
L: II, III 
R: II, III 
L: II, III  
− 0.5 − 0.6 no no 





L: II  
− 2.4 <0.1 no no 
10 T3 N2c Oropharynx HPV+
Grade 2 
R: II, III 
L: II; III 
R: II, III 
L: II; III  
3.1 1.2 no no 
11 T2 N2b Oropharynx HPV- 
Grade 3 
R: II, III 
L: - 
UFND  0.4 UFND no no 
12 T4a N2c Oropharynx HPV- 
Grade 3 
R: Ib, II, III 
L: III, IVa 
R: Ib, II, III 
L: III, IVA  
− 2.5 − 0.2 no no 
13 T4b N2c Hypopharynx 
Grade 3 
R: II, VIb, VIIa 
L: - 
UFND  25.5 UFND no no 




UFND  0.6 UFND no no 
15 T4a N2b Oral cavity 
Grade 2 
R: II, VIIa 
L: - 
R: II, VIIa 
L: -  
− 1.4 − 0.2 no no 





L: 1b  
− 2.1 <0.1 no no 
17 T4a N2b Oral cavity 
Grade 2 
R: Ib, II, III 
L: - 
R: Ib, II, III, IVa, Vb 
L: -  
2.2 18.2 +elective & high 
risk vol. 
no 
18 T4a N2c Oral cavity 
Grade 2 
R: Ib, II, III 
L: Ib, II, III 
R: Ib, II, III 
L: Ib, II, III  
7.1 − 2.6 +high risk vol. no 
19 T3 N2b Oropharynx HPV- 
Grade 2 
R: - 
L: II, III 
R: - 
L: II, III  
4.7 2.9 +high risk vol. no 
20 T2 N2b Oral cavity 
Grade 2 
R: II, III, IVa 
L: - 
R: II, III, IVa 
L: -  
0.6 − 0.9 +high risk vol. no 
21 T4a N2c Oral cavity 
Grade 2 
R: II, III, IVa 
L: Ib, II, III, IVa 
R: II, III, IVa 
L: Ib, II, III, IVa  
22.9 50.7 +high risk vol. no 
22 T4a N2b Oral cavity 
Grade 3 
R: I, II, III 
L: - 
R: I, II, III 
L: III, IVa  
13.5 9.5 +elective & high 
risk vol. 
yes 
23 T3 N2b Oral cavity 
Grade 3 
R: II, III 
L: - 
R: II, III 
L: -  
1.5 0.6 +high risk vol. no 





L: III, IVa  
1.4 − 4.3 +elective & high 
risk vol. 
no 
25 T4a N2c Oropharynx HPV+
Grade 3 
R: Ib, II, III 
L: Ib, II, III 
R: Ib, II, III 
L: Ib, II, III  
116.5 2.3 +high risk vol. no 
26 T4a N2c Larynx 
Grade 3 
R: II, III, IVa 
L: II, IVa 
R: II, III, IVa 
L: II, III, IVa  
− 2.5 1.2 +high risk vol. no 
27 T4a N2b Oropharynx HPV- 
Grade 3 
R: - 
L: II, III 
R: - 
L: Ib, II, III  
3.7 0.6 +high risk vol. yes 
28 T4a N2c Oropharynx HPV- 
Grade 2 
R: Ib 
L: Ib, II, III, IVa 
R: Ib, II, III, IVa 
L: Ib, II, III, IVa  
1.1 2.7 +elective & high 
risk vol. 
no 
29 T2 N2b Hypopharynx 
Grade 3 
R: - 
L: II, III 
R: - 
L: Ib, II, III  
− 0.2 1.3 +elective & high 
risk vol. 
no 




R: II, III 
L: II, III  
2.3 3.4 +elective & high 
risk vol. 
yes 




R: II, III, IVa 
L: -  
5.3 8.4 +elective & high 
risk vol. 
no 




R: II, III 
L: II, III, Va + b  
7.9 0.4 +elective & 
+high risk vol. 
no 
MTV: metabolic tumor volume; L: left; R: right; UFND: upfront neck dissection; vol.: volume. 
cT, cN and cM stages according to the Union for Cancer Control, 7th Edition. 
* Would the new high-risk volume (defined by the second PET/CT) be covered by the initially planned elective volume? 
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strategy by treatment intensification, such as the addition of concomi-
tant chemotherapy, altered fractionation or switch to primary surgery, 
corresponding to a major treatment change. Finally, yet importantly, the 
issue of cost effectiveness caused by repeated PET/CT is not trivial. In 
this context, the impact of an incorrect treatment indication (major 
treatment change) or an inadequate RT plan (minor treatment change) 
on tumor control and survival is substantial, and diagnosis by means of 
PET/CT was shown to be cost-effective in the long term [26–28]. 
Nevertheless, the potential long-term benefit of a second-look exami-
nation should be further investigated and validated. The question about 
the possible clinical advantage of repeated PET/CT in comparison with 
contrast-enhanced planning-CT only could be adequately addressed and 
answered in such a manner. Nevertheless, the current rates of locore-
gional control in comprehensive cancer centers would require a high 
number of patients in such cohorts to determine a statistically significant 
influence of the strategy demonstrated here. 
Approximately 155 primary LAHNSCC cases are diagnosed annually 
and staged with PET/CT in our center. Although 32 patients within four 
years indicated good quality in terms of treatment delays, the sample 
size remained relatively small for the purposes of this study. Additional 
limitations of our study are due to its retrospective nature. Some clinical 
parameters, such as smoking and the exact reasons for the delay, could 
not be clearly defined. The time interval between the examinations was 
heterogeneous, although it did not seem to have a substantial impact or 
predictive value on the results. Moreover, it is possible that the rate of 
upstaging and treatment changes would be slightly different if four pa-
tients had not undergone upfront neck dissection. 
Conclusion 
A second look PET/CT due to a delay of more than four weeks to RT 
in LAHNSCC or in case of clinical suspicion of tumor progression led to 
tumor upstaging in 13% of patients and changes in treatment planning 
in more than half of patients, which is expected to directly influence 
oncologic outcome. 
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